Ron Sabo - Concepedia

Author

Ron Sabo

Novartis (United States)

Also Known As

R SABO, R Sabo, R. Sabo, RON SABO, Ron Sabo

Publications

906

Citations

H-Index

Concepts

All Affiliations

Novartis (United States)Novartis (France)Novartis (Switzerland)Boston Biomedical Research Institute Pharmaceutical Product Development (United States)

About

Ron Sabo is an author at Novartis (United States) specializing in medicine, pharmacotherapy, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	227
2	Diabetes	3	3	72
3	Allergy	1	1	17
4	Immunology	1	1	17
5	Nutrition	1	1	48

Ron Sabo

Publications

878

Citations

H-Index

Page 1

	Year	Citations
A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C Paul Glue, Régine Rouzier‐Panis, C Raffanel, Hepatology	2000	248
Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers* Richard D. Huhn, Elaine Radwanski, Jose Gallo, Clinical Pharmacology & Therapeutics	1997	129
The Absolute Oral Bioavailability and??Population-Based Pharmacokinetic Modelling of a Novel Dipeptidylpeptidase-IV Inhibitor, Vildagliptin, in Healthy Volunteers Yanling He, Brian M. Sadler, Ron Sabo, Clinical Pharmacokinetics Pharmacokinetic ModelingNovel Dipeptidylpeptidase-iv InhibitorHealthy VolunteersPharmacologyAbsolute Oral Bioavailability	2007	74
The effect of age, gender, and body mass index on the pharmacokinetics and pharmacodynamics of vildagliptin in healthy volunteers Yanling He, Ron Sabo, Joelle Campestrini, British Journal of Clinical Pharmacology	2007	65
The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin Yanling He, Ron Sabo, Joelle Campestrini, European Journal of Clinical Pharmacology Liver PhysiologyPharmacologyHepatic ImpairmentHepatitisHepatotoxicity	2007	64
Dose Proportionality and the Effect of Food on Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, in Healthy Volunteers Gangadhar Sunkara, Ron Sabo, Yibin Wang, The Journal of Clinical Pharmacology NutritionDose ProportionalityDiabetes ManagementHealthy SubjectsHealthy Volunteers	2007	48
Vildagliptin, a Novel Dipeptidyl Peptidase IV Inhibitor, Has No Pharmacokinetic Interactions With the Antihypertensive Agents Amlodipine, Valsartan, and Ramipril in Healthy Subjects Yanling He, Monica Ligueros‐Saylan, Gangadhar Sunkara, The Journal of Clinical Pharmacology	2007	43
Pharmacokinetics of Roxithromycin (RU 965) Howard B. Lassman, Surendra K. Puri, Irwin Ho, The Journal of Clinical Pharmacology	1988	40
Evaluation of Pharmacokinetic Interactions Between Vildagliptin and Digoxin in Healthy Volunteers Yanling He, Ron Sabo, Gangadhar Sunkara, The Journal of Clinical Pharmacology	2007	40
Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects Yanling He, Ron Sabo, Gilles‐Jacques Rivière, Current Medical Research and Opinion	2007	38

Page 1